Skip to content
Triangle logo TriangleGet started
← Study library

NCT01160380 · REGISTRY CONDITION SEARCH

A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE3
Status at capture
COMPLETED
Registry last update
2014-11-06

The purpose of this study is to evaluate the efficacy of armodafinil for the treatment of cancer-related fatigue in adult patients with multiple myeloma. The study consists of a screening period, followed by a 56-day treatment phase, and a final assessment to occur 28 days after the end of the last treatment.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

BFI Score

→

outcome · POSTED

Trail Making Test B Score (TMT-B)

→

outcome · POSTED

Symbol Digit Modalities Test Score (SDMT)

→

outcome · POSTED

Digit Span Test Score

→

outcome · POSTED

Functional Assessment of Cancer Therapy - Fatigue (FACIT-F) Score

→

outcome · POSTED

Hospital Anxiety and Depression Scale (HADS) Score

→

outcome · POSTED

Epworth Sleepiness Scale (ESS) Score

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * The patient has been diagnosed with multiple myeloma based on standard criteria * The patient is diagnosed with cancer-related fatigue based on ICD-10 diagnostic criteria * The patient shows signs of severe fatigue as evidenced by a Brief Fatigue Inventory score of at least 4 * The patient is a man or woman aged 18 years or older at the time of informed consent * The patient has given voluntary written informed consent before any study-related procedure is performed which is not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care * Women of child bearing potential must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study. * Men must agree to use an acceptable method of contraception throughout the study and for 90 days after last dose study drug * The patient must be willing and able to comply with study restrictions * The patient must have an ECOG performance status not greater than 2 * The patient must have a life-expectancy of greater than 3 months * The patient must meet the following laboratory criteria within 14 days of enrollment: * Platelet count greater than 50 x 109/L * Absolute neutrophil count greater than 0.5 x 109/L * Hemoglobin greater than 8 g/dL * AST and ALT not greater than 3.0 x the upper limit of normal (ULN) * Serum bilirubin not greater than 2.0 x ULN * Calculated or measured creatinine clearance of at least 10 mL/minute Exclusion Criteria: * The patient has been concurrently diagnosed with clinically significant depression * The patient is concurrently enrolled in another investigational study that does not apply to the specific treatment of multiple myeloma * The patient is receiving an investigational agent (non-FDA-approved) for any reason within 28 days of starting treatment on this study * The patient has previously received armodafinil * The patient has received modafinil or a psychostimulant within 14 days of enrollment * The patient has received a blood transfusion within 14 days of enrollment * The patient has impaired cardiac function or clinically significant cardiac diseases * The patient has other concurrent severe and/or uncontrolled medical or psychiatric conditions including abnormal laboratory values, that could cause unacceptable safety risks or compromise compliance with the protocol * The patient has known positivity for human immunodeficiency virus (HIV) or hepatitis B or C; baseline testing for HIV and hepatitis B or C is not required * The patient has undergone major surgery within 28 days of enrollment or has not recovered from side effects of such therapy (Kyphoplasty is not considered to be a major surgery; however, the investigator is to discuss enrollment of a patient with a recent history of kyphoplasty with Oncotherapeutics' medical monitor) * The patient has a significant history of noncompliance to medical regimens or unwilling or unable to comply with the instructions given to him or her by the study staff * The patient has a history of skin reactions and/or known sensitivity attributable to compounds of similar chemical or biological composition to modafinil, armodafinil, or the inactive ingredients in armodafinil including lactose monohydrate, starch, microcrystalline cellulose, croscarmellose, sodium, magnesium stearate or povidone * The patient is a pregnant or lactating woman. Any women becoming pregnant during the study will be withdrawn from the study * The patient is male whose sexual partner is a woman of childbearing potential not using effective birth control
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    The patients receive armodafinil for all 56 days of the study.
    intervention Names
    1. Drug: armodafinil
    label
    Armodafinil
    type
    EXPERIMENTAL
  2. description
    These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
    intervention Names
    1. Drug: armodafinil
    2. Drug: Placebo
    label
    Placebo-First
    type
    PLACEBO_COMPARATOR
interventions
  1. arm Group Labels
    1. Armodafinil
    2. Placebo-First
    description
    Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.
    name
    armodafinil
    other Names
    1. Nuvigil
    type
    DRUG
  2. arm Group Labels
    1. Placebo-First
    description
    Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.
    name
    Placebo
    other Names
    1. sugar-pill
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
CROSSOVER
masking Info
masking
QUADRUPLE
who Masked
  1. PARTICIPANT
  2. CARE_PROVIDER
  3. INVESTIGATOR
  4. OUTCOMES_ASSESSOR
primary Purpose
SUPPORTIVE_CARE
Enrollment
count
50
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Survey measuring fatigue. The scale contains 9 items; range=0-90 (0-10 per item). Mild = 1-3 Moderate = 4-7 Severe = 8-10
    measure
    BFI Score
    time Frame
    Day 1, Day 28 and Day 56
  2. description
    Cognitive test that gives a measure of various aspects of cognitive performance. Used to measure cognitive fatigue. The test consists of 25 circles containing 13 sequential numbers (1-13) and 12 sequential letters (A-L) positioned. The test evaluates the time to correctly order letters and numbers; low times = better performance.
    measure
    Trail Making Test B Score (TMT-B)
    time Frame
    Day 1, Day 28 and Day 56
  3. description
    Test to evaluate neurocognitive functions (attention, visual scanning and motor speed). The test consists of a key =9 graphic symbols numbered 1 to 9 and the test =120 graphic symbols to be matched with its number. The test evaluates the number of correct matches within 90 seconds. Higher scores= better performance
    measure
    Symbol Digit Modalities Test Score (SDMT)
    time Frame
    Day 1, Day 28 and Day 56
  4. description
    Test evaluates working memory and attention. The test consists of repeat numeric sequences of 2 to 9 numbers forward or backwards and evaluates the number of items from a sequence correctly named. Higher scores = better performance.
    measure
    Digit Span Test Score
    time Frame
    Day 1, Day 28 and Day 56
secondary Outcomes
  1. description
    Survey addressing fatigue and patient happiness, coping, etc. Used to assess quality of life. The test consists of 40 items, each item with a response scale of 0-4. Higher scores denote better status Items are added to provide the total score (range 0-160).
    measure
    Functional Assessment of Cancer Therapy - Fatigue (FACIT-F) Score
    time Frame
    Day 1, Day 28 and Day 56
  2. description
    Survey used to assess depression and anxiety. The test consists of 14 items (7 for anxiety and 7 for depression); there are 4 possible answers for each statement. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. Higher scores= more anxiety or depression.
    measure
    Hospital Anxiety and Depression Scale (HADS) Score
    time Frame
    Day 1, Day 28 and Day 56
  3. description
    Survey assessing sleep patterns. The test consists of 8 items. The response scale range is 0-24 (range 0-3 per item: 0-No chance to falling asleep; 3-high chance of falling asleep). Interpretation: 0-No chance to falling asleep; 10+ above average chance daytime sleepiness
    measure
    Epworth Sleepiness Scale (ESS) Score
    time Frame
    Day 1, Day 28 and Day 56
Full study description
brief Summary
The purpose of this study is to evaluate the efficacy of armodafinil for the treatment of cancer-related fatigue in adult patients with multiple myeloma. The study consists of a screening period, followed by a 56-day treatment phase, and a final assessment to occur 28 days after the end of the last treatment.
detailed Description
This is a Phase III, multi-center, double-blind, randomized, placebo-controlled, crossover study to evaluate the efficacy of armodafinil at a dosage of 150 mg/day for the treatment of cancer-related fatigue (CRF) in adult patients with multiple myeloma. The study consists of a screening period, followed by a 56 day treatment phase, and a final assessment to occur 28 days after the end of the last treatment. The screening period will occur within 14 days before baseline, where "baseline" refers to day 1 when assessments will be made before drug administration. During this period, a medical history will be obtained along with a complete physical examination including vital sign measurements and Eastern Cooperative Oncology Group (ECOG) performance status. Clinical laboratory tests including hematology, clinical chemistry (blood urea nitrogen \[BUN\], serum creatinine, total bilirubin, alkaline phosphatase, aspartate aminotransferase \[AST\] and alanine aminotransferase \[ALT\]), electrolytes (potassium, sodium, chloride and calcium), random glucose, total protein, albumin, and urinalysis will also be performed during the screening period as well as serum pregnancy tests for women of childbearing potential. During the screening period, patients will also be assessed for the presence of cancer-related fatigue using the International Classification for Disease Tenth Edition (ICD-10) diagnostic criteria and the Brief Fatigue Inventory (BFI). Only those patients showing evidence of cancer-related fatigue will be enrolled in the study. The criteria for inclusion for any given patient consist of meeting the International Classification for Disease Tenth Edition (ICD-10) criteria for cancer-related fatigue and a score ≥ 4 on the BFI. ICD-10 CRF classification will be established using a standard interview guide. Patients eligible for the study will be randomized to either receive armodafinil at an initial fixed dosage of 150 mg/day (Group A) or a placebo (Group B) during the first 28 days of the treatment phase. On day 29, patients randomized to receive placebo will then cross over to receive armodafinil at a dosage of 150 mg/day until day 56. Group A patients randomized to receive armodafinil will continue their current treatment with the drug until day 56. The duration of the treatment phase is 56 days. Assessments for CRF will be conducted on day 1 (baseline) prior to drug treatment, and after drug administration on days 15, 28, 43, and 56. These assessments will be conducted as verbal interviews, paper-and-pencil surveys, paper-and-pencil tests, and electronic tests as appropriate per assessment. During the treatment phase, each patient will also have clinical laboratory tests performed on days 1, 15, 28, 43 and 56 to monitor for potential toxicity. Additional procedures performed at these visits will include monitoring for adverse events, review of concomitant medications and other support therapies (e.g., growth factors and transfusion), ECOG performance status, vital signs measurements, and physical examinations. Twenty-eight days after the last dose of study drug, patients are to complete a final assessment (herein referred to as the end-of-treatment visit). Procedures to be conducted at this visit include measurement of vital signs, a complete physical examination, assessment of adverse events, a review of concomitant medications, assessment of ECOG performance status, hematology and clinical chemistry laboratory tests including electrolytes, total protein and albumin. Patients who withdraw from the study before the completion of the 56 day cycle will still have all end-of-treatment assessments performed 28 days after their last dose of study drug.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-b05a0fab38310522227e
      requested nct id
      NCT01160380
      primary nct id
      NCT01160380
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      a67dc34f85d114695f691081423808e35ee9a9aff23bcfa354f8bdcab1cd2d59
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-b05a0fab38310522227e
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01160380
      occurrences
      1. context exact
        NCT01160380
        end
        11
        exact text
        NCT01160380
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/867/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      49ba5e969f46b4abde0db3780dd499a5dd2124beddb059f1c4049dab3a41015e

    Preserved source evidence · Not medical advice